BOSTON (TheStreet) -- Let's kick off this week's Biotech Stock Mailbag with a tweet rather than an email.
Via Twitter, @bobbandera asks, "Any opinion on the Keryx Biopharmaceuticals (KERX) data released for its colon cancer drug?"
The Keryx cancer drug in question is perifosine and much of the data presented this week are not new, but first released last May at the American Society of Clinical Oncology (ASCO) annual meeting. Here's what I wrote about the perifosine data last May:
"The data presented on perifosine at ASCO came from a small, randomized phase II study in patients with second- or third-line metastatic colon cancer. Patients treated with a combination of perifosine and the chemotherapy Xeloda reported that it took 28.9 weeks before their tumors started growing again. That's more than double the 11 weeks for patients treated with Xeloda alone."Twenty percent of patients in the perifosine arm of the study reported tumor shrinkage compared to 7% for patients in the Xeloda-alone arm. Perifosine patients were also living longer, although survival data is not yet mature." On Monday, Keryx presented an update to this perifosine trial. Importantly, the now-mature survival data looks strong, with median overall survival of 18 months for the perifosine-Xeloda patients compared to 11 months for the Xeloda-alone patients. The survival benefit was statistically significant in favor of perifosine. The rest of the efficacy data -- response rate and progression-free survival -- remained unchanged from when the data were first presented last May. These data are certainly encouraging, but as I noted last May, this phase II study was small, with only 38 patients enrolled. And only half the patients in the study received prior treatment with Erbitux or Vectibix, the two colon cancer drugs from the EGFR inhibitor class marketed by Eli Lilly (LLY) and Amgen (AMGN), respectively, that are commonly used in second- and third-line colon cancer patients.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV